SAE2 appears to play an essential role in SCLC tumorigenesis, metastasis, and chemosensitivity, indicating that it could serve as a promising biomarker and therapeutic target for SCLC patients, especially those with high c-Myc expression. Here, MYC is linked to small cell lung carcinoma.